The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkin, Samuel J. P., Russel-Szymczyk, Monika, Psota, Marek, Hlavinkova, Lucia, Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822857/
https://www.ncbi.nlm.nih.gov/pubmed/31168765
http://dx.doi.org/10.1007/s12325-019-00965-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822857/
https://www.ncbi.nlm.nih.gov/pubmed/31168765
http://dx.doi.org/10.1007/s12325-019-00965-y

Ejemplares similares